Cancer Screening Success Has Penny Stock Surging

CHEK stock could be spooking shorts

Digital Content Manager
Jul 9, 2019 at 10:15 AM
facebook twitter linkedin

Biotech stock Check-Cap Ltd (NASDAQ:CHEK) rallied out of the gate this morning, after the firm announced positive final results for its C-Scan test, used to detect precancerous polyps in patients at risk for colon cancer. CHEK stock surged as high as $2.57 earlier, and was last seen up 6% at $2.31.

In fact, the equity is set for its first close atop its 40-day moving average -- a trendline that's served as recent pressure on the charts -- in almost two months. From a longer-term perspective, the security has been trading in a channel of lower highs and lows since mid-March, following a rejection at its 200-day moving average.

While analysts are pretty quiet on the biopharma name, the two who follow the stock are resoundingly optimistic, both calling it a "buy" or better. Plus, the consensus 12-month target price of $10.50 more than quadruples CHEK's current perch, and represents a level the equity hasn't traversed since May 2018. 

An unwinding of shorts could provide some addition tailwinds on the charts. Short interest spiked 20.1% in the last two reporting periods, and now represents 7.2% of the stock's available float. At CHEK's average pace of trading, it would take over seven days to cover all these bearish bets, leaving the door open for a short squeeze. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners